Aeva and ZF Bring First FMCW LiDAR to Automotive Production
8.9.2020 16:00:00 EEST | Business Wire | Press release
Aeva, a leader in next generation sensing and perception systems, and ZF, a top global automotive Tier-1 supplier, are partnering to bring the world’s first Frequency Modulated Continuous Wave (FMCW) LiDAR to the automotive market. The partnership — Aeva's expertise in FMCW LiDAR technology combined with ZF's experience in industrialization of automotive grade sensors — represents a key commitment to accelerate mass production of safe and scalable 4D LiDAR technology for autonomous driving applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200908005368/en/
Aeva and ZF partner for production of first automotive grade FMCW LiDAR for automated driving. (Photo: Business Wire)
“From early on we have believed in building an ecosystem of the world’s most capable partners across the industry and this partnership is one part of that plan. ZF’s capability as one of the largest Tier-1s globally with expertise in automotive scale production of sensing systems is a key step to accelerating the introduction of safe and scalable autonomous vehicles,” said Soroush Salehian, Co-Founder of Aeva. “The industry is at the cusp of deploying the next generation of sensing to realize the adoption of highly automated and autonomous cars and we believe Aeva’s 4D LiDAR will be an indispensable part of this next chapter.”
About the Partnership
Aeva and ZF aim to bring the first automotive grade 4D LiDAR to market for autonomous driving applications. The partnership strengthens the parties’ collaboration by leveraging Aeva’s unique expertise in FMCW LiDAR and perception technology together with ZF’s expertise as a leading automotive supplier, autonomous systems provider, and market leader in smart cameras and the corresponding production know-how. The final system is targeted as a key solution for autonomous driving applications including established truck and OEM manufacturers as well as leading mobility as a service customers.
“LiDAR is a key technology for systems and sensing in the area of highly automated and autonomous driving. Aeva’s unique FMCW technology combines long range performance and direct velocity measurements, making it the right choice for autonomous driving applications. We have seen that different markets require different solutions. For L2+/L3 systems a package and cost optimized Lidar is crucial. For applications which feature L4 and further solutions, the focus lies on range and direct velocity measurement, as edge performance is key for the virtual driver software stack.
Aeva’s FMCW technology approach perfectly meets all the stringent requirements for autonomous operations in trucks and robo-service vehicles. We look forward to bring the world’s first FMCW LiDAR to an automotive grade level and scale production, where ZF can rely on a long-lasting production experience in optical sensors. ‘Automotive Grade’ will become a quality seal, necessary for a solid business model of all autonomous vehicle software stack providers,” said Torsten Gollewski, Executive Vice President Autonomous Mobility Solutions at ZF.
As part of the partnership, Aeva will be responsible for the FMCW LiDAR core sensing functionality, performance and algorithms and ZF will be responsible for industrialization of the automotive grade sensing system that meets all automotive requirements.
What makes Aeva’s 4D LiDAR unique?
Aeva’s FMCW technology is designed to meet the challenging performance and the manufacturability requirements for adoption of LiDAR in autonomous vehicles.
Unlike other LiDAR technologies, Aeva’s 4D LiDAR-on-chip uses a continuous laser beam to measure the change in frequency of the waveform as it reflects off of an object. This allows it to detect an object’s range and instant velocity simultaneously beyond 300 meters at high accuracy. Aeva’s 4D LiDAR is also completely free of interference from other sensors or sunlight and it operates at only fractions of the optical power typically required to achieve long range performance. All of which are critical hurdles that have previously slowed the broad adoption of automotive LiDAR.
Aeva’s technology also differs from other FMCW approaches in its unique ability to break the dependency between maximum range and points density. Aeva’s 4D LiDAR integrates multiple beams on a chip that is produced at silicon wafer scale. Each beam is uniquely capable of measuring multiple millions of points per second at maximum range providing unprecedented data fidelity and significantly enhancing the factor of safety for self-driving cars.
About Aeva
Aeva was founded in 2017 by Soroush Salehian, and Mina Rezk -- previously engineering leaders at Apple & Nikon. Headquartered in Mountain View, California, Aeva is building the next-generation of sensing and perception for autonomous vehicles that is safe, simple, and scalable. Aeva is backed by Volkswagen’s Porsche SE, Lux Capital and Canaan Partners, amongst others. For more information, visit www.aeva.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200908005368/en/
Contact information
Michelle Chang
Press@aeva.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
